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Abstract
Background: Bilateral testicular neoplasia is rare, with an incidence ranging from 1 to 5 %. Long-term survival has
improved in recent years due to advanced diagnostic approaches and new therapeutic methods that are highly
effective against germ cell tumors.
Case presentation: We present the case of a patient with a primary seminomatous testicular tumor, who
developed a contralateral metastasis and a subsequent metachronous tumor following chemotherapy and
consolidation radiotherapy treatment.
Conclusions: Strict follow-up, including physical examination and ultrasound examination of the contralateral testis,
enabled early diagnosis of the second tumor, giving the patient a high likelihood of a definitive cure.
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Background
Testicular germ cell tumors (TGCTs) represent 1–2 %
of all cancers in men and are the most common solid
tumors found in male adolescents and young adults
between 15 and 35 years of age [1]. The mean age at
diagnosis is 34 years (median, 39.5 years) [2]. Most
testicular tumors (95 %) arise from germ cells and can
be divided into two main groups: seminomas and non-
seminomas. Previous TGCT is a risk factor for contralat-
eral malignancy development [3]. Compared with age-
matched populations, patients with a history of TGCT
show a 23–27 times greater relative risk of developing a
contralateral germ cell tumor [4].
Bilateral testicular germ cell tumors (BTGCTs) occur
with a global incidence ranging from 1 to 7.8 % [1, 5, 6].
Bilateral testicular tumors that occur simultaneously are
termed synchronous tumors, while those occurring at dif-
ferent times are termed metachronous tumors. Metachro-
nous BTGCTs are twice as prevalent as synchronous
tumors [7] and are defined by an interval of > 6 months be-
tween neoplasm occurrences [8]. In cases of metachronous
BTGCT, the second tumor usually occurs within 5 years
after the first tumor.
Case presentation
A 35-year-old man with no known risk factors for
testicular malignancy presented at the urology depart-
ment with a right testicular mass causing painful swell-
ing. He had been experiencing discomfort and heaviness
for 10 days. His general practitioner had started anti-
biotic and anti-inflammatory treatment a week prior to
his arrival at our department. The patient had no past
medical history of testicular issues.
Physical examination revealed a lump, which testicular
ultrasound confirmed as an 18 mm× 12 mm× 25 mm
heterogeneous hypoechogenic mass localized to the upper
pole of the right testis (Fig. 1). A computed tomography
(CT) scan showed no evidence of abdominopelvic or
thoracic metastases. The blood serum tumor marker
levels were as follows: human chorionic gonadotropin
(HCG) < 1.20 U/ml (normal is < 5.01 U/ml); α-fetoprotein
(AFP) = 3.4 ng/ml (normal is < 7 ng/ml); and lactate de-
hydrogenase (LDH) = 599 IU/l (normal is 313–618 IU/l).
A right inguinal radical orchiectomy was performed in
September of 2009. Histological examination revealed a
pure seminoma of 4 cm × 2.5 cm, without lymphatic,
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vascular, or tunica albuginea infiltration. The tumor node
metastasis (TNM) classification was pT1pNxpMx accord-
ing to the Union for International Cancer Control (UICC)
staging system, seventh edition. Two weeks after the
surgery, this case was discussed during a multidisciplinary
uro-oncology meeting. From October 21 to November 10
of 2009, the patient underwent adjuvant radiotherapy with
doses of 25.2 Gy delivered to the paraaortic lymph nodes
in 14 fractions.
The patient was considered to be disease-free and
received follow-up in accordance with our standard
protocol, which includes chest and abdominal CT, phys-
ical examination, and tumor marker assessment every
4 months for the first 2 years, and testicular ultrasound
of the contralateral side once each year. A total-body CT
scan at 1 year after radical surgical treatment showed a
16-mm lymph node under the patient’s left collarbone
(Fig. 2a, b). The lesion was confirmed by positron emis-
sion tomography (PET) scan, and surgical node excision
was performed. Histological examination revealed a typ-
ical seminoma (Fig. 3a, b). Chemotherapy was initiated
with a bleomycin, etoposide, and cisplatin (BEP) proto-
col administered every 21 days for 2 cycles from October
to December of 2010.
Four years later, a follow-up ultrasound of the left
testis revealed a 15 mm× 6 mm node with microcalcifi-
cations (Fig. 4a, b). Blood serum tumor markers were
normal, and a CT scan showed no evidence of abdomi-
nopelvic or thoracic metastasis. The possibility of radical
or partial orchiectomy was discussed with the patient. In
March of 2014, the patient underwent left inguinal tes-
ticular exploration of the lesion with ultrasound image
guidance and excisional biopsy. Analysis of frozen biopsy
sections revealed a seminomatous tumor with an intense
chronic granulomatous inflammatory lesion. Due to the
diffuse nature of the tumor, radical left orchiectomy was
performed. The final pathological diagnosis was a pure
seminoma that presented as isolated and scattered neo-
plastic cells within an inflammatory and granulomatous
reaction and multifocal intratubular germ cell neoplasia
(IGGNU).
The patient remained under surveillance and received
androgen replacement therapy with long-acting testoster-
one undecanoate every 12 weeks (Nebido®). A bilateral
testicular prosthesis was proposed but was refused. Sperm
cryopreservation was not performed because the patient
had children and did not desire any additional offspring.
Follow-up was performed following the standard protocol.
At 2 years after left radical orchiectomy, the patient
remained disease free. At the most recent visit, the patient
reported maintenance of libido, no adverse effects from
the androgen replacement therapy, and comfortable sex-
ual activity and quality of life.
Discussion
Reported TGCT incidence rates from multiple coun-
tries between 1991 and 2011 show geographical varia-
tions, with the highest rates observed in Denmark.
Over recent decades, TGCT prevalence has gradually
increased in most populations of European origin and
in the USA [9, 10]. Some studies suggest an increased
incidence of bilateral disease in the post-chemotherapy
and radiotherapy era [11, 12]. A retrospective review
shows a threefold higher incidence of bilateral testicular
cancers in the post-chemotherapy era compared to the
pre-chemotherapy era [13]. The apparent increase in the
Fig. 1 Testicular ultrasound showing an 18 mm× 12 mm× 25 mm
heterogeneous hypoechogenic mass localized to the upper pole of
the right testis (arrows)
Fig. 2 a, b Full-body computed tomography scan showing a 16-mm lymph node under the left collarbone (arrows)
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number of metachronous tumors may reflect the in-
creased life expectancy of the general population as well
as the prolonged survival associated with higher cure rates
for initial tumors.
A systematic literature review—including 50,376 men
with TGCT between 1991 and 2011 from many coun-
tries—reported a BTGCT prevalence of 1.82 % [7].
Among those with BTGCT, 69.2 % had metachronous
tumors and 30.8 % had synchronous tumors. Several
studies indicate that metachronous testicular tumors seem
to be more frequent than synchronous ones [14, 15]. Bilat-
eral metachronous TGCT was first described in a case
report in 1942. Metachronous testicular cancer is diag-
nosed when at least 6 months elapse between the appear-
ance of the first tumor and the second tumor and when
there is an ultrasound-documented absence of a contralat-
eral mass at diagnosis of the first tumor.
Among patients with metachronous tumors, the mean
age at diagnosis of the first tumor is 28 years old and
the mean age at diagnosis of the second tumor is
35 years old [11]. Our present patient was 36 years old
when the first tumor was diagnosed and 40 years old
when the second tumor was diagnosed. In 70 % of cases,
the second testicular malignancy arises within 5 years
after the first TGCT [2]. Seminoma is the most common
histological type of bilateral testicular cancer, comprising
approximately 68 % of such cases [9], as well as the most
common histological type of metachronous tumor [16].
When the second tumor is a seminoma, the median
interval between tumors seems to be longer (~10 years)
[17]. There have been 25 reported cases of BTGCT in
which the contralateral testicular tumor occurred 20 years
or more after the original tumor. Within a series of 25
cases, 4 cases involved a second tumor that occurred at
least 30 years after the original testicular tumor, with the
longest interval being 40 years [11, 12]. Contralateral
testicular seminoma can occur even at an advanced age,
underscoring the importance of life-long follow-up for
these patients [17, 18].
The incidence of metachronous germ cell tumors in
patients diagnosed with a seminoma is influenced by the
patient’s age at the time of the initial diagnosis. Evidence
suggests that men who develop a seminoma when they
are 30 years of age or younger may be at greater risk of
developing a second tumor [2, 15]. Patients diagnosed
with a seminomatous tumor at less than 30 years of age
Fig. 3 Histological examination revealed a typical seminoma. a Hematoxylin-eosin staining, ×200 magnification. b Immunoperoxidase staining
using an anti-PLAP antibody, ×400 magnification
Fig. 4 a, b Ultrasound of the left testis revealing a 15 mm× 6 mm node with microcalcifications (arrows)
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show an increased risk of relapse in the following
15 years compared to men who are over 30 years old at
diagnosis (3.1 vs 1.2 %) [19].
Although the etiology of BTGCT remains unknown,
both genetic and environmental causes are implicated.
Presently known epidemiological risk factors for TGCT
development include a history of cryptorchidism, Kline-
felter syndrome, the presence of a contralateral tumor,
infertility, and a history of testis cancer in first-degree
relatives [17]. The elevated risk in family members and
associations with inherited genotypes suggest genetic
causes [20, 21]. On the other hand, testicular cancer
incidence rates nearly doubled in industrialized coun-
tries between 1975 and 2007, suggesting an influence of
environmental factors [9, 22]. Our present case involved
no known genetic or environmental risk factors.
In our present case, serum markers were negative both
at the diagnosis of the first tumor and at tumor recur-
rence. This is in accordance with the typical presentation
of a seminoma. Most second tumors are discovered by
the physician via scrotal ultrasonography or by the pa-
tient via testicular self-examination. Ultrasonography is
a safe and simple screening procedure. One major diffi-
culty regarding the diagnosis of second tumors is that
patients may be reluctant to seek help due to fear of
castration.
Ultrasound detection of microlithiasis in the contralat-
eral testis is associated with a 30-fold increase in the risk
of presenting with a second TGCT, and diagnosis of the
first tumor is associated with a 5–8 % risk of testicular
intraepithelial neoplasm (TIN) in the contralateral testis.
These data highlight the need for long-term surveillance
to support early detection of the second TGCT. Within
7 years, 70 % of all TINs will progress to invasive
neoplasia [23, 24], although this risk is somewhat lower
among patients who undergo chemotherapy for their
first tumor. The 5-year survival rates for men with
synchronous and metachronous bilateral testicular
tumor are 88 and 95 %, respectively [7], suggesting that
metachronous tumors have a more favorable survival
outcome than synchronous tumors. Synchronous tumors
are also associated with more advanced disease than
metachronous tumors [7]. Among patients with bilateral
testicular cancer, 70 % present with stage I disease upon
diagnosis of the second tumor. This is most likely due to
close follow-up and increased patient awareness.
The optimal management of patients with intratubular
germ cell neoplasms remains controversial. The choices
include surveillance and irradiation of the contralateral
testis. Since radiotherapy can result in infertility and
may affect Leydig cell function [1], surveillance is an
important part of TGCT follow-up. Clear guidelines are
also lacking for treatment of bilateral testicular tumors.
Treatment of the second tumor is based on the stage
and histology [11]. The incidence of contralateral tes-
ticular cancer is not significantly influenced by the use
of radiation therapy for the initial testicular cancer [25].
Treatment for advanced germ cell tumors includes
combination chemotherapy with bleomycin, cisplatin,
and etoposide, followed by surgical salvage for residual
disease. Depending of the patient’s risk profile, 3–4 cycles
of chemotherapy are needed [26]. The patient in our
present case received adjuvant radiation therapy after
the onset of the first tumor as well as chemotherapy.
Additionally, a metastatic lymph node was removed at
relapse, which occurred long before the diagnosis of the
second tumor. Notably, 5 years elapsed between diagno-
sis of the first and second tumors. A left radical orchid-
ectomy was performed to eliminate the recurrent tumor
due to its diffuse character and the history of metastases.
Sparing the testis would have carried a risk of recur-
rence. Taking into account that he did not desire more
children, the patient wanted radical surgery despite the
need for hormonal replacement.
In the present case, the detection of a contralateral
supradiaphragmatic lymph node 3 years prior to the
contralateral testis diagnosis indicated metastatic relapse.
A review by Cooper et al. reported that approximately
75 % of seminomas present as stage 1, with disease limited
to the testis [27]. All tumors of germ cell origin have the
propensity to metastasize via lymphatic pathways, which
typically occurs in a sequential pattern, beginning with
abdominal lymph node involvement, followed by succes-
sive involvement of lymph nodes in the chest and neck
[28]. Wood et al. demonstrated that cervical metastasis is
almost exclusively left-sided, with 21 of 23 patients show-
ing disease in supraclavicular or scalene lymph nodes [28].
Metastatic tumors can also appear in locations outside of
the direct line of spread from the primary site [29]. A
review by Vledder reported that 4 % of seminoma patients
showed cervical metastasis and that only 5 % of these
patients had the neck mass as their initial disease sign
[30]. Seminomas can metastasize to the supraclavicular
lymph nodes, and tumors from the right testis can spread
to the interaortocaval, precaval, and paraaortic regions,
with crossover to left-sided lymph nodes. The left testis
drains into the paraaortic and preaortic regions. Interaor-
tocaval lymph node involvement occurs in higher-stage
disease. From there, the tumors usually grow along the
thoracic duct into the left supraclavicular lymph node and
the subclavian vein and then show disseminated spread
[31]. This hypothesis may be applicable to our present
patient, since metastasis was not found elsewhere.
Conclusions
Patients with a primary testicular tumor carry an in-
creased risk of supraclavicular lymph node metastasis des-
pite radiotherapy, and a metachronous second primary
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tumor can arise even with chemotherapy. A strict follow-
up protocol involving physical and ultrasound evaluation
of the contralateral testis supports early diagnosis of a
second tumor, increasing the chance of a definitive cure.
Notably, metachronous tumors may occur long after the
initial tumor diagnosis. Treatment of the second tumor is
dictated by its histology and its pathological and clinical
stage at the time of diagnosis. Hormonal testosterone
replacement can help promote a good quality of life.
Consent
The patient gave written informed consent for the publi-
cation of this case report and any accompanying images.
A copy of this written consent is available for review by
the Editor-in-Chief of this journal.
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